19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

BEAM News
Member News
Events

Latest news of BEAM Alliance

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

09 September 2019 - Nabriva Therapeutics GmbH

Nabriva’s XENLETA™ (lefamulin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Now Available in the U.S.

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

06 September 2019 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Earns $5 Million Milestone Payment under its License Agreement with Sinovant Sciences

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.…

20 August 2019 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)

“Today’s approval of XENLETA is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and…

22 July 2019 - AMR Centre Ltd

The AMR Centre set for partnership with Shionogi for new superbug therapy

Dr Peter Jackson, executive director of the AMRC, said: “COT-143 is an advanced program that has produced very promising data…

17 July 2019 - Polyphor Ltd

Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options

“We would like to thank the patients, the investigators and all the scientists involved for their contribution to the development…

16 July 2019 - Pherecydes Pharma

Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections

“This project will be an important step forward for phage therapy and a new hope for patients,” commented Guy-Charles Fanneau…

page 1/14

Events

13 December 2019

JPIAMR Hacking AMR 2019

Finding digital solutions to fight Antimicrobial Resistance is our theme for this special international JPIAMR hackathon. The hackathon aim is…

13 November 2019

Matchmaking Symposium ‘Emerging Antimicrobials and Diagnostics in AMR 2019’

The event provides an excellent podium for emerging Antimicrobials and Diagnostics as well as an exciting program including orchestrated matchmakings,…

11 November 2019

BIO-Europe, 25th Annual International Partnering Conference

Celebrating 25 years of facilitating partnerships that drive life science dealmaking!

07 November 2019

World Anti-Microbial Resistance Congress

The conference gathers global leaders in infectious diseases to meet, brainstorm and discuss the challenges and opportunities on seven topic…

07 November 2019

REVIVE webinar: Converting Gram-positive-only compounds into broad-spectrum antibiotics

This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail…

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

03 October 2019

REVIVE webinar: Natural products antibiotics: from traditional screening to novel discovery approaches

In this webinar, Olga Genilloud will discuss the role of natural products in current antibiotic discovery.

02 October 2019

IDWeek 2019

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America…

25 September 2019

Phage Futures Europe

Translating phage-based applications into clinically and commercially viable therapeutics

page 1/4